In vitro Susceptibility Testing of GSK656 against mycobacteria species.
In this study, we aimed to assess in vitro susceptibility of GSK656 against multiple mycobacteria species, and investigate the correlation between sequence variations within LeuRS and in vitro susceptibility of GSK656 between mycobacteria species. A total of 187 mycobacteria isolates, comprising 105 Mycobacterium tuberculosis (MTB) and 82 nontuberculous mycobacteria (NTM), were randomly selected for the determination of in vitro susceptibility. For MTB, 102 out of 105 isolates had MICs ≤0.5 mg/L, demonstrating a MIC50 of 0.063 mg/L and a MIC90 of 0.25 mg/L, respectively. An ECOEF value of 0.5 mg/L was proposed for identifying GSK656-resistant MTB. For NTM, the MIC50s and MIC90s were both >8.0 mg/L for M. intracellulare and M. avium, respectively. In contrast, all M. abscessus isolates had MICs ≤0.25 mg/L, yielding a MIC90 of 0.063 mg/L. LeuRS from M. abscessus showed higher sequence similarity with MTB LeuRS than LeuRSs from M. avium and M. intracellulare Sequence alignment revealed 28 different residues between LeuRSs from M. avium and M. intracellulare and LeuRSs from MTB and M. abscessus Among them, 15 residues were in the drug binding domain. Structure modeling revealed that several different residues were close to the tRNA-LeuRS interface or the entrance of drug-tRNA binding pocket. In conclusion, our data demonstrate that GSK656 exhibits significant species diversity in in vitro susceptibility against various mycobacteria species. GSK656 has potent efficacy against MTB and M. abscessus, whereas the inherent resistance is noted in M. intracellulare and M. avium.